Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

SOX11, CCND1, BCL1/Igh, and Igh-VDJ – a Plethora of Markers for Minimal Residual Disease in Mantle Cell Lymphoma: Which One to Choose?

Anita Tranberg Simonsen, MSc., Marie Schou, Camilla Darum Sørensen, MSc., Peter Hokland, MD DMSc, Hans Bentzen, MD PhD, Charlotte Guldborg Nyvold, MSc, PhD

Blood (2014) 124 (21): 2957.

https://doi.org/10.1182/blood.V124.21.2957.2957

Published: 2014

Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod

Blood (2014) 124 (21): 5435.

https://doi.org/10.1182/blood.V124.21.5435.5435

Published: 2014

Journal Articles

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Blood (2014) 123 (19): 2953–2959.

https://doi.org/10.1182/blood-2013-12-541953

Published: 2014

Journal Articles

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Blood (2012) 120 (21): 747.

https://doi.org/10.1182/blood.V120.21.747.747

Published: 2012

Journal Articles

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Blood (2009) 114 (22): 932.

https://doi.org/10.1182/blood.V114.22.932.932

Published: 2009

NARROW

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

SOX11, CCND1, BCL1/Igh, and Igh-VDJ – a Plethora of Markers for Minimal Residual Disease in Mantle Cell Lymphoma: Which One to Choose?

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Email alerts

ASH Publications

American Society of Hematology

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

SOX11, CCND1, BCL1/Igh, and Igh-VDJ – a Plethora of Markers for Minimal Residual Disease in Mantle Cell Lymphoma: Which One to Choose?

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only